Document is current
Any future updates will be listed below
-
Authors
van der Walt, Anneke https://orcid.org/0000-0002-4278-7003
Strijbis, Eva M. M. https://orcid.org/0000-0001-6705-5864
Bridge, Francesca
Coetzee, Timothy https://orcid.org/0000-0002-3031-7549
Graves, Jennifer
Brownlee, Wallace J.
Butzkueven, Helmut https://orcid.org/0000-0003-3940-8727
Marrie, Ruth Ann
Hua, Le H.
Lampe, Anna https://orcid.org/0000-0002-5799-6457
Tintore, Mar https://orcid.org/0000-0001-9999-5359
Montalban, Xavier
Calabresi, Peter A.
Barkhof, Frederik https://orcid.org/0000-0003-3543-3706
,
Abdelhak, Ahmed
Amato, Maria Pia
Amezcua, Lilyana
Azevedo, Christina J.
Banwell, Brenda
Bar-Or, Amit
Bebo, Bruce F.
Chataway, Jeremy
Corboy, John R.
Correale, Jorge
Dawson, Valina Lynn
Finlayson, Marcia
Fujihara, Kazuo
Hawton, Annie
Hellwig, Kerstin
Kappos, Ludwig
Kos, Daphne
Krysko, Kristen M.
Kuhle, Jens
Frenay, Christine Lebrun
Lublin, Fred D.
Magyari, Melinda
Miller, Aaron E.
Moccia, Marcello
Morrow, Sarah A.
Mowry, Ellen M.
Oh, Jiwon
Pontillo, Giuseppe
Ramanathan, Sudarshini
Rocca, Maria A.
Salter, Amber
Salvetti, Marco
Sastre-Garriga, Jaume
Smith, Kathryn E.
Sormani, Maria Pia
Stankoff, Bruno
Tremlett, Helen
Weinstock-Guttman, Bianca
Wiendl, Heinz
Zaratin, Paola
Zhang, Yinan
- License Information
-
More Information
Article History
Accepted: 16 June 2025
First Online: 23 July 2025
Competing interests
: A.v.d.W. has received unrestricted research grants from Biogen, Merck and Novartis; and has served on advisory boards for Biogen, Merck, Novartis and Roche, and received speaker’s honoraria and travel support from these companies. E.M.M.S. has received speaker fees from Merck and Novartis. F.Br. has received travel support from Biogen and Novartis. T.C. has received travel support from the Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis and Sanofi. J.G. has served as a consultant for Google and on concluded advisory boards for Horizon. W.J.B. has received speaker honoraria and/or acted as a consultant for AstraZeneca, Biogen, Merck, Neuraxpharm, Novartis, Roche, Sandoz and Sanofi. H.B. declares that his institute has received compensation for advisory board or lecture fees from Biogen, Merck, Novartis, Roche and UCB Pharma; and his institute receives research funding from Biogen, Merck, Novartis and Roche. R.A.M is a co-investigator on studies that have received funding from Biogen, the Pfizer Foundation and Roche Canada. L.H.H. has served as a consultant to Alexion, EMD Serono, Genentech, Genzyme, Horizon, Novartis and TG Therapeutics; has served on scientific advisory boards for EMD Serono, Genentech and Novartis; has received non-promotional speaker honoraria from Genzyme and TG Therapeutics; and has received research funding paid directly to her institute from Biogen and Genentech. M.T. has received compensation for consulting services, speaking honoraria and research support from Almirall, Bayer Schering Pharma, Biogen, Genzyme, Immunic Therapeutics, Janssen, Merck–Serono, Novartis, Roche, Sanofi-Aventis, Teva Pharmaceuticals and Viela Bio; and has served on Data Safety Monitoring Boards for Parexel and UCB Biopharma, and on the Relapse Adjudication Committee for Imcyse. X.M.’s institution has received compensation for lecture honoraria and travel expenses, participation in scientific meetings, clinical trial steering committee membership or clinical advisory board participation from AbbVie, Actelion, Alexion, Bial, Biogen, Bristol Myers Squibb (Celgene), EMD Serono, Genzyme, Immunic Therapeutics, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Neuraxpharm, Novartis, Peervoice, Roche, Samsung-Biosys, Sandoz, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics and Excemed. P.A.C. has served on advisory boards for Eli Lilly and Novartis, and is principal investigator on a research grant from Genentech. F.Ba. is a Steering Committee or Data Safety Monitoring Board member for Biogen, Eisai, Merck and Prothena, and is an advisory board member for Alzheimer Europe, Combinostics and Scottish Brain Sciences; has been a consultant for Bracco, Celltrion, Merck, Roche, and Rewind Therapeutics; has research agreements with Alzheimer’s Disease Data Initiative, Biogen, GE Healthcare, Merck and Roche; and is a co-founder and shareholder of Queen Square Analytics. A.L. declares no competing interests.
Free to read: This content has been made available to all.
